Welcome to our dedicated page for Celgene SEC filings (Ticker: CELG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Celgene's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Celgene's regulatory disclosures and financial reporting.
Bristol Myers Squibb reported first quarter 2026 revenue of $11.5 billion, up 3% year over year (1% Ex-FX). The Growth Portfolio generated $6.2 billion, rising 12% (9% Ex-FX), while the Legacy Portfolio declined to $5.3 billion, down 6%.
Key products included Eliquis with $4.1 billion in worldwide sales, up 16%, and strong growth from newer brands such as Camzyos, Breyanzi, Reblozyl and Opdualag. U.S. revenue was $7.8 billion, down 1%, and international revenue was $3.7 billion, up 11% (4% Ex-FX).
GAAP diluted EPS increased to $1.31 from $1.20, while non-GAAP EPS decreased to $1.58 from $1.80, reflecting higher research and development spending and lower other income. Net income attributable to the company was $2.7 billion on a GAAP basis and $3.2 billion on a non-GAAP basis.
The company reaffirmed its 2026 non-GAAP guidance, including total revenue of ~$46.0–$47.5 billion and non-GAAP diluted EPS of $6.05–$6.35, with both revenue and EPS expected to trend toward the upper end of these ranges.
Bristol Myers Squibb reported first quarter 2026 revenue of $11.5 billion, up 3% year over year (1% Ex-FX). The Growth Portfolio generated $6.2 billion, rising 12% (9% Ex-FX), while the Legacy Portfolio declined to $5.3 billion, down 6%.
Key products included Eliquis with $4.1 billion in worldwide sales, up 16%, and strong growth from newer brands such as Camzyos, Breyanzi, Reblozyl and Opdualag. U.S. revenue was $7.8 billion, down 1%, and international revenue was $3.7 billion, up 11% (4% Ex-FX).
GAAP diluted EPS increased to $1.31 from $1.20, while non-GAAP EPS decreased to $1.58 from $1.80, reflecting higher research and development spending and lower other income. Net income attributable to the company was $2.7 billion on a GAAP basis and $3.2 billion on a non-GAAP basis.
The company reaffirmed its 2026 non-GAAP guidance, including total revenue of ~$46.0–$47.5 billion and non-GAAP diluted EPS of $6.05–$6.35, with both revenue and EPS expected to trend toward the upper end of these ranges.
Bristol-Myers Squibb Co reported that Vanguard Capital Management beneficially owned 153,108,018 shares of common stock, representing 7.49% of the class as of 03/31/2026. The filing lists sole dispositive power for 153,108,018 shares and sole voting power for 20,787,778 shares. The Schedule 13G was signed on 04/29/2026 by Ashley Grim.
Bristol-Myers Squibb Co reported that Vanguard Capital Management beneficially owned 153,108,018 shares of common stock, representing 7.49% of the class as of 03/31/2026. The filing lists sole dispositive power for 153,108,018 shares and sole voting power for 20,787,778 shares. The Schedule 13G was signed on 04/29/2026 by Ashley Grim.
Bristol Myers Squibb EVP and CFO David V. Elkins reported open-market sales of company stock. On April 1, 2026, he sold 25,519 shares of common stock at a weighted average price of $61.60 per share and 4,481 shares at $62.05 per share, totaling 30,000 shares. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. After the sales, he directly held 159,248 shares of Bristol Myers Squibb common stock and had an additional 294.42 shares held indirectly through the BMS Savings and Investment Program, based on a recent 401(k) plan statement.
Bristol Myers Squibb EVP and CFO David V. Elkins reported open-market sales of company stock. On April 1, 2026, he sold 25,519 shares of common stock at a weighted average price of $61.60 per share and 4,481 shares at $62.05 per share, totaling 30,000 shares. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. After the sales, he directly held 159,248 shares of Bristol Myers Squibb common stock and had an additional 294.42 shares held indirectly through the BMS Savings and Investment Program, based on a recent 401(k) plan statement.
Bristol Myers Squibb director Phyllis R. Yale received 577.082 Deferred Share Units as a compensation award. The grant was valued at $60.65 per unit and is linked to an equal number of underlying common shares. Following this award, she holds 43,903.777 Deferred Share Units in total.
The units will convert into common stock when she leaves the board or on a future date she previously chose. Her balance includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Phyllis R. Yale received 577.082 Deferred Share Units as a compensation award. The grant was valued at $60.65 per unit and is linked to an equal number of underlying common shares. Following this award, she holds 43,903.777 Deferred Share Units in total.
The units will convert into common stock when she leaves the board or on a future date she previously chose. Her balance includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Theodore R. Samuels II received a grant of 845.012 Deferred Share Units as compensation. These units are tied to Bristol Myers Squibb common stock at a reference price of $60.65 per unit.
Each Deferred Share Unit converts into one share of common stock when his board service ends or on a future date he previously selected. Following this award, he holds a total of 68,727.516 Deferred Share Units, which also reflect deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Theodore R. Samuels II received a grant of 845.012 Deferred Share Units as compensation. These units are tied to Bristol Myers Squibb common stock at a reference price of $60.65 per unit.
Each Deferred Share Unit converts into one share of common stock when his board service ends or on a future date he previously selected. Following this award, he holds a total of 68,727.516 Deferred Share Units, which also reflect deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Derica W. Rice received a grant of 638.912 Deferred Share Units on common stock. The award is classified as a grant or other acquisition, not an open-market purchase or sale. Each unit will convert into one share of common stock upon settlement.
The Deferred Share Units become settleable when Rice ceases to be a director or at a future date previously specified. Following this grant, Rice holds a total of 39,963.721 Deferred Share Units, which include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Derica W. Rice received a grant of 638.912 Deferred Share Units on common stock. The award is classified as a grant or other acquisition, not an open-market purchase or sale. Each unit will convert into one share of common stock upon settlement.
The Deferred Share Units become settleable when Rice ceases to be a director or at a future date previously specified. Following this grant, Rice holds a total of 39,963.721 Deferred Share Units, which include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Michael R. McMullen received a grant of Deferred Share Units as board compensation. On March 31, 2026, he was awarded 577.082 Deferred Share Units, with a reference price of $60.65 per unit.
Each unit will convert into one share of common stock upon settlement, which occurs when he ceases to be a director or on a future date he previously selected. After this award, he holds 15,556.771 Deferred Share Units, including deferred compensation and reinvested dividends under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Michael R. McMullen received a grant of Deferred Share Units as board compensation. On March 31, 2026, he was awarded 577.082 Deferred Share Units, with a reference price of $60.65 per unit.
Each unit will convert into one share of common stock upon settlement, which occurs when he ceases to be a director or on a future date he previously selected. After this award, he holds 15,556.771 Deferred Share Units, including deferred compensation and reinvested dividends under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Peter J. Arduini received a grant of 577.082 Deferred Share Units, each tied to common stock valued at $60.65 per unit. After this compensation award, he directly holds a total of 71,435.166 Deferred Share Units.
Each Deferred Share Unit will convert into one share of common stock when the units are settled. Settlement occurs when Arduini ceases to be a director or on a future date he previously specified. The reported holdings include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Peter J. Arduini received a grant of 577.082 Deferred Share Units, each tied to common stock valued at $60.65 per unit. After this compensation award, he directly holds a total of 71,435.166 Deferred Share Units.
Each Deferred Share Unit will convert into one share of common stock when the units are settled. Settlement occurs when Arduini ceases to be a director or on a future date he previously specified. The reported holdings include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol-Myers Squibb Co ownership disclosure: The Vanguard Group filed Amendment No. 10 to report 0 shares beneficially owned of Common Stock, representing 0% of the class. The filing states this reporting change follows an internal realignment and disaggregation of certain Vanguard subsidiaries in accordance with SEC Release No. 34-39538, with affected subsidiaries reporting separately after the realignment.
Bristol-Myers Squibb Co ownership disclosure: The Vanguard Group filed Amendment No. 10 to report 0 shares beneficially owned of Common Stock, representing 0% of the class. The filing states this reporting change follows an internal realignment and disaggregation of certain Vanguard subsidiaries in accordance with SEC Release No. 34-39538, with affected subsidiaries reporting separately after the realignment.